Your browser doesn't support javascript.
loading
Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation.
Bornancin, Frédéric; Renner, Florian; Touil, Ratiba; Sic, Heiko; Kolb, Yeter; Touil-Allaoui, Ismahane; Rush, James S; Smith, Paul A; Bigaud, Marc; Junker-Walker, Ursula; Burkhart, Christoph; Dawson, Janet; Niwa, Satoru; Katopodis, Andreas; Nuesslein-Hildesheim, Barbara; Weckbecker, Gisbert; Zenke, Gerhard; Kinzel, Bernd; Traggiai, Elisabetta; Brenner, Dirk; Brüstle, Anne; St Paul, Michael; Zamurovic, Natasa; McCoy, Kathy D; Rolink, Antonius; Régnier, Catherine H; Mak, Tak W; Ohashi, Pamela S; Patel, Dhavalkumar D; Calzascia, Thomas.
Afiliação
  • Bornancin F; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Renner F; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Touil R; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Sic H; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Kolb Y; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Touil-Allaoui I; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Rush JS; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Smith PA; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Bigaud M; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Junker-Walker U; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Burkhart C; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Dawson J; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Niwa S; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Katopodis A; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Nuesslein-Hildesheim B; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Weckbecker G; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Zenke G; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Kinzel B; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Traggiai E; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Brenner D; Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2C1, Canada; Department of Infection and Immunity, Luxembourg Institute of Health, L-4354 Esch-Sur-Alzette, Luxembourg;
  • Brüstle A; Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2C1, Canada; Department of Immunology, John Curtin School of Medical Research, The Australian National University, Canberra ACT 2601, Australia;
  • St Paul M; Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2C1, Canada;
  • Zamurovic N; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • McCoy KD; Maurice Müller Laboratories, University Clinic for Visceral Surgery and Medicine, University of Bern, 3010 Bern, Switzerland; and.
  • Rolink A; Developmental and Molecular Immunology, Department of Biomedicine, University of Basel, 4058 Basel, Switzerland.
  • Régnier CH; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Mak TW; Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2C1, Canada;
  • Ohashi PS; Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2C1, Canada;
  • Patel DD; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland;
  • Calzascia T; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland; thomas.calzascia@novartis.com.
J Immunol ; 194(8): 3723-34, 2015 Apr 15.
Article em En | MEDLINE | ID: mdl-25762782
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diferenciação Celular / Linfócitos T Reguladores / Caspases / Proliferação de Células / Encefalomielite Autoimune Experimental / Linfócitos B Reguladores / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Immunol Ano de publicação: 2015 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diferenciação Celular / Linfócitos T Reguladores / Caspases / Proliferação de Células / Encefalomielite Autoimune Experimental / Linfócitos B Reguladores / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Immunol Ano de publicação: 2015 Tipo de documento: Article País de publicação: Estados Unidos